These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 20495208)

  • 1. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
    Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
    Shakya N; Sane SA; Vishwakarma P; Gupta S
    Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.
    Shivahare R; Vishwakarma P; Parmar N; Yadav PK; Haq W; Srivastava M; Gupta S; Kar S
    PLoS One; 2014; 9(4):e94596. PubMed ID: 24732039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.
    Gupta S; Sane SA; Shakya N; Vishwakarma P; Haq W
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3461-4. PubMed ID: 21537026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
    Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
    J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
    Shakya N; Sane SA; Haq W; Gupta S
    Parasitol Res; 2012 Aug; 111(2):563-70. PubMed ID: 22392136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
    Seifert K; Croft SL
    Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
    Sane SA; Shakya N; Gupta S
    Exp Parasitol; 2011 Feb; 127(2):376-81. PubMed ID: 20846525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.
    Shakya N; Sane SA; Gupta S
    Parasitol Res; 2011 Apr; 108(4):793-800. PubMed ID: 21212980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
    Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
    Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 16. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
    Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
    Shivahare R; Ali W; Vishwakarma P; Natu SM; Puri SK; Gupta S
    Acta Trop; 2015 Oct; 150():35-41. PubMed ID: 26119043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.
    Shakya N; Sane SA; Shankar S; Gupta S
    Peptides; 2011 Oct; 32(10):2131-3. PubMed ID: 21959258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fucoidan cures infection with both antimony-susceptible and -resistant strains of Leishmania donovani through Th1 response and macrophage-derived oxidants.
    Kar S; Sharma G; Das PK
    J Antimicrob Chemother; 2011 Mar; 66(3):618-25. PubMed ID: 21393231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
    Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
    Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.